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Research Questions
Comparing Prevalence of Medication-Related Osteonecrosis of the Jaw (MRONJ) 
due to Denosumab and Bisphosphonates as a Side Effect of Osteoporosis Treatment
Kendra Apland PA-S
Department of Physician Assistant Studies, University of North Dakota School of Medicine & Health Sciences
Grand Forks, ND  58202-9037
Abstract
Introduction
Applicability to Clinical Practice
References
As the baby boomer generation continues to age, the diagnosis of 
osteoporosis and its side effects will continue to increase. Denosumab and 
bisphosphonates (BPs) are some of the most common medication classes 
used to treat osteopenia and osteoporosis, but it is believed that both 
medications have the possible side effect of medication-related 
osteonecrosis of the jaw (MRONJ). The purpose of this paper is to uncover 
if MRONJ is a side effect of osteoporosis treatment and which medication 
carries the highest incidence rate. Through a review of several electronic 
databases and several peer reviewed research articles, a wide range of 
reported incidence rates of MRONJ for both medications were uncovered, 
along with many compounding possible risk factors. There is a wide range 
of reported incidence rates among different studies. My research found that 
denosumab carries a slightly higher risk of MRONJ versus 
bisphosphonates, but the difference was found to be statistically 
insignificant. Uncovered risk factors include increasing age, gender, recent 
dental procedures, history of oral disease, and corticosteroid use. My 
research is impactful in the fact that as providers, we can be better informed 
about the differences between denosumab and bisphosphonates and the 
possible risk factors of MRONJ. We can use the information, along with 
possible other risk factors and our patient’s history, to make joint decisions 
about what osteoporosis medication is right for our patients. 
Keywords: osteonecrosis, jaw, medication-related, bisphosphonates side 
effects, denosumab side effects, abnormal fracture, osteoporosis
Statement of the Problem
There are many different approaches to treating osteoporosis. 
Denosumab and bisphosphonates are two of the most common 
pharmacologic treatments prescribed. However, both are not without 
their various side effects. Both medications are believed to have the 
possible side effect of osteonecrosis of the jaw, but this is believed to 
be very rare.
 Is the incidence rate of MRONJ greater in those patients 
treated with denosumab or bisphosphonates?
 Are there any precipitating factors or conditions that 
increases incidence rates of MRONJ with treatment of 
denosumab or bisphosphonates?
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 The world’s population is ageing: two factors—longer life spans and 
aging baby boomers—will combine to double the population of 
Americans aged 65 years and older during the next 25 years to about 72 
million (CDC, 2013). 
 This will have a significant impact on age-related health care; a loss of 
bone mineralization and mass in the forms of osteopenia and 
osteoporosis being a major issue.
 Worldwide, osteoporosis causes more than 8.9 million fractures 
annually, resulting in an osteoporotic fracture every three seconds 
(International Osteoporosis Foundation, 2017).
 In addition to the personal burden and impact on quality of life, the 
costs associated with fracture treatment and rehabilitation are enormous.
 A study from 2002 estimated national health care expenditures due to 
osteoporosis fractures to be about $12 billion annually, with about 75% 
of the costs going to direct medical care (Desai, Duncan, Sloan, 2003). 
 Incidence rates of MRONJ:
 General population:
 0.000006% to 0.001% (Syejda et al., 2016) and (DynaMed Plus, 
2017)
 BP:
 Between 0% to 0.2%; up to 6.7% (Loyson, et al., 2017)
 13.1 times greater in patients on BP therapy vs placebo group 
(Dodson, 2014)
 Denosumab: 
 0.04% to 10% (Loyson et al., 2017)
 15.5% after BP and then denosumab (Loyson et al, 2017). 
 Slightly higher risk of MRONJ early after switching from BPs to 
denosumab compared to patients remaining on BPs
 Based on global incidence rates, the switch from BPs to 
denosumab can be considered as safe as initially starting 
denosumab therapy (Loyson et al., 2017).
 Contributing factors:
 Cancer treatment: The risk in cancer patients is about 50-100 times 
greater than in patients exposed to placebo (Dodson, 2014).
 Duration of treatment: incidence is higher with longer duration of 
treatment, particularly when therapy exceeds four years (Up to Date, 
2017).
 Operative treatment: dental procedures that invade bone increase risk 
(De Paula, Black, & Rosen, 2016).
 52 to 61% of MRONJ patients reported tooth extraction as the 
precipitating event (Ruggiero et al., 2014).
 Demographic, systemic, other factors:
 Age and gender are variably reported as risk factors.
 Tobacco use has been inconsistently reported as a risk factor.
 Corticosteroids are associated with an increased risk as they can 
further weaken bones (Ruggiero et al., 2014).
 Patients with a single nucleotide polymorphism (SNP) in a specific 
gene associated with bone density and collagen formation were 5.8 
times more likely to develop MRONJ (Ruggiero et al., 2014).
 Studies suggest a likely genetic link between MRONJ and BP 
therapy.
Medication
Indications for 
treatment
Placebo IV BP Oral BP Denosumab Study design
Malignancy
Qi et al (2013) 0% 
(1450)
1.1% 
(2928)
1.9% (4585) Systemic 
review
Scagliotti et al 
(2012)
0.8% 
(400)
0.7% (411) RCT
Coleman et al 
(2001)
0% 
(1675)
0.7% 
(1665)
RCT
Vahtsevanos et al 
(2009)
6.7% 
(1163)
Prospective 
cohort study
Mauri et al (2009) 0.019% 
(5382)
0.33% 
(3987)
Systemic 
review
Osteoporosis
Papapoulos et al 
(2012)
0% 
(3383)
0.04% (4549) RCT
Sugimoto et al., 
2014
0.1% (775) RCT
Grbic et al (2010) 0.020% 
(4945)
0.017% 
(5864)
Systemic 
review
Malden and 
Lopes (2012)
0.004% 
(90000)
Prospective 
cohort study
Lo et al (2010) 0.1% 
(8572)
Cross-
sectional
 Is the incidence rate of MRONJ greater in those patients treated 
with denosumab or bisphosphonates?
 A wide variety of incidences rates were reported with both 
medications.
 Several studies have reported a slightly higher rate with 
denosumab compared to BPs, but the differences are not 
statistically significant (Berenson, Stopeck 2017). See Table 1
 Moreover, the risk of MRONJ in osteoporotic patients continues 
to be very low regardless of drug type or dosing schedule 
(Ruggiero et al., 2014).
 Many studies used different doses, administration schedules, 
sample sizes, and patients with varying comorbidities, making it 
difficult to compare the results with full confidence.
 In general practice, it can also be difficult to identify the 
medication to blame, because of the common practice of how and 
when these medications are prescribed. 
 Are there any precipitating factors or conditions that increases 
incidence rates of MRONJ with treatment of denosumab or 
bisphosphonates?
 Cancer can greatly increase a patient’s risk for MRONJ, but again 
the prevalence rates reported vary greatly from 1-15% and up to 50-
100 times higher than a patient in the control group.
 This may be due to the higher dosages used for cancer treatment 
versus dose used for osteoporosis.
 There are many different comorbidities that greatly increase the 
MRONJ risk.
 One of the greatest risk factors is dental procedures and current 
oral disease.
 Other risk factors include increasing patient age and gender and 
family history.
 Corticosteroid use can also increase a patient’s risk.
 Tobacco has been inconsistently reported as a risk factor.
 In summary, my research is mostly inconclusive.
 Although I was not successful in answering one of my research 
questions, I believe my research was successful as it allows for the 
acquisition of knowledge and application to future practice.
 As potential future providers, a large proportion of our patients will 
most likely be elderly, so it is imperative to be aware of common 
conditions that could affect this population, like osteoporosis.
 Both conditions can be debilitating and cause significant physical 
impairment and fractures if left untreated, a major concern being hip 
fractures.
 Hip fractures in particular are associated with significant increased risk 
of mortality, loss of independence, and financial burden.
 In one study, the reported one-year mortality after sustaining a hip 
fracture was estimated to be 14% to 58% (Schnellet et al., 2010).
 There are many different treatment options for osteoporosis, among 
them BPs and denosumab, and there is not a one-size-fits-all solution.
 In any situation, we as providers have to be able to weigh the benefits of 
treating versus the possible risks of treating. 
 We will need to take each patient’s preference and personal medical 
history in to account to make a joint decision about osteoporosis 
treatment.
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